{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T11:16:28Z","timestamp":1792062988075,"version":"4.4.0"},"reference-count":82,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T00:00:00Z","timestamp":1658361600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"DFG","award":["EXC 2145 SyNergy \u2013 ID 390857198"],"award-info":[{"award-number":["EXC 2145 SyNergy \u2013 ID 390857198"]}]},{"name":"DFG","award":["HA1737\/16-1"],"award-info":[{"award-number":["HA1737\/16-1"]}]},{"name":"NIH","award":["RF1 AG006173"],"award-info":[{"award-number":["RF1 AG006173"]}]},{"name":"NIH","award":["P01 AG015379"],"award-info":[{"award-number":["P01 AG015379"]}]},{"name":"David APP Fund at BWH"}],"content-domain":{"domain":["www.plosbiology.org"],"crossmark-restriction":false},"short-container-title":["PLoS Biol"],"abstract":"<jats:p>Strong genetic evidence supports an imbalance between production and clearance of amyloid \u03b2-protein (A\u03b2) in people with Alzheimer disease (AD). Microglia that are potentially involved in alternative mechanisms are actually integral to the amyloid cascade. Fluid biomarkers and brain imaging place accumulation of A\u03b2 at the beginning of molecular and clinical changes in the disease. So why have clinical trials of anti-amyloid therapies not provided clear-cut benefits to patients with AD? Can anti-amyloid therapies robustly decrease A\u03b2 in the human brain, and if so, could this lowering be too little, too late? These central questions in research on AD are being urgently addressed.<\/jats:p>","DOI":"10.1371\/journal.pbio.3001694","type":"journal-article","created":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T17:23:36Z","timestamp":1658424216000},"page":"e3001694","update-policy":"https:\/\/doi.org\/10.1371\/journal.pbio.corrections_policy","source":"Crossref","is-referenced-by-count":145,"title":["If amyloid drives Alzheimer disease, why have anti-amyloid therapies not yet slowed cognitive decline?"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4869-1627","authenticated-orcid":true,"given":"Christian","family":"Haass","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8846-9767","authenticated-orcid":true,"given":"Dennis","family":"Selkoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,7,21]]},"reference":[{"issue":"6","key":"pbio.3001694.ref001","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/ca.980080612","article-title":"An English translation of Alzheimer\u2019s 1907 paper, \"Uber eine eigenartige Erkankung der Hirnrinde\".","volume":"8","author":"A Alzheimer","year":"1995","journal-title":"Clin Anat"},{"issue":"2","key":"pbio.3001694.ref002","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1016\/S2468-2667(21)00249-8","article-title":"Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019.","volume":"7","author":"Collaborators GBDDF","year":"2022","journal-title":"Lancet. Public Health"},{"issue":"4","key":"pbio.3001694.ref003","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/s41573-022-00391-w","article-title":"The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics","volume":"21","author":"E Karran","year":"2022","journal-title":"Nat Rev Drug Discov"},{"issue":"6393","key":"pbio.3001694.ref004","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/359322a0","article-title":"Amyloid beta-peptide is produced by cultured cells during normal metabolism","volume":"359","author":"C Haass","year":"1992","journal-title":"Nature"},{"issue":"5045","key":"pbio.3001694.ref005","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1126\/science.1738847","article-title":"Processing of the amyloid protein precursor to potentially amyloidogenic derivatives","volume":"255","author":"TE Golde","year":"1992","journal-title":"Science"},{"issue":"2","key":"pbio.3001694.ref006","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrm2101","article-title":"Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer\u2019s amyloid beta-peptide","volume":"8","author":"C Haass","year":"2007","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"5054","key":"pbio.3001694.ref007","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1126\/science.1566067","article-title":"Alzheimer\u2019s disease: the amyloid cascade hypothesis","volume":"256","author":"JA Hardy","year":"1992","journal-title":"Science"},{"issue":"6","key":"pbio.3001694.ref008","doi-asserted-by":"crossref","first-page":"595","DOI":"10.15252\/emmm.201606210","article-title":"The amyloid hypothesis of Alzheimer\u2019s disease at 25 years","volume":"8","author":"DJ Selkoe","year":"2016","journal-title":"EMBO Mol Med"},{"issue":"4","key":"pbio.3001694.ref009","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/0896-6273(91)90052-2","article-title":"The molecular pathology of Alzheimer\u2019s disease","volume":"6","author":"DJ Selkoe","year":"1991","journal-title":"Neuron"},{"issue":"4","key":"pbio.3001694.ref010","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.cell.2015.12.056","article-title":"The Cellular Phase of Alzheimer\u2019s Disease","volume":"164","author":"B De Strooper","year":"2016","journal-title":"Cell"},{"issue":"6106","key":"pbio.3001694.ref011","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/325733a0","article-title":"The precursor of Alzheimer\u2019s disease amyloid A4 protein resembles a cell-surface receptor","volume":"325","author":"J Kang","year":"1987","journal-title":"Nature"},{"issue":"2","key":"pbio.3001694.ref012","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/ana.410410220","article-title":"Plasma levels of amyloid beta proteins Abeta1-40 and Abeta1-42(43) are elevated in Down\u2019s syndrome.","volume":"41","author":"T Tokuda","year":"1997","journal-title":"Ann Neurol"},{"issue":"1","key":"pbio.3001694.ref013","doi-asserted-by":"crossref","first-page":"18","DOI":"10.2174\/1567205012666151020114607","article-title":"Aging in Down Syndrome and the Development of Alzheimer\u2019s Disease Neuropathology.","volume":"13","author":"E Head","year":"2016","journal-title":"Curr Alzheimer Res"},{"issue":"1","key":"pbio.3001694.ref014","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/ng1718","article-title":"APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy","volume":"38","author":"A Rovelet-Lecrux","year":"2006","journal-title":"Nat Genet"},{"issue":"3","key":"pbio.3001694.ref015","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/ana.410430316","article-title":"Molecular mapping of Alzheimer-type dementia in Down\u2019s syndrome","volume":"43","author":"VP Prasher","year":"1998","journal-title":"Ann Neurol"},{"issue":"6347","key":"pbio.3001694.ref016","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/353844a0","article-title":"Early-onset Alzheimer\u2019s disease caused by mutations at codon 717 of the beta-amyloid precursor protein gene","volume":"353","author":"MC Chartier-Harlin","year":"1991","journal-title":"Nature"},{"issue":"6311","key":"pbio.3001694.ref017","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/349704a0","article-title":"Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer\u2019s disease","volume":"349","author":"A Goate","year":"1991","journal-title":"Nature"},{"issue":"5","key":"pbio.3001694.ref018","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/ng0892-345","article-title":"A pathogenic mutation for probable Alzheimer\u2019s disease in the APP gene at the N-terminus of beta-amyloid","volume":"1","author":"M Mullan","year":"1992","journal-title":"Nat Genet"},{"issue":"6405","key":"pbio.3001694.ref019","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/360672a0","article-title":"Mutation of the beta-amyloid precursor protein in familial Alzheimer\u2019s disease increases beta-protein production","volume":"360","author":"M Citron","year":"1992","journal-title":"Nature"},{"issue":"5094","key":"pbio.3001694.ref020","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1126\/science.8424174","article-title":"Release of excess amyloid beta protein from a mutant amyloid beta protein precursor","volume":"259","author":"XD Cai","year":"1993","journal-title":"Science"},{"issue":"5163","key":"pbio.3001694.ref021","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1126\/science.8191290","article-title":"An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants.","volume":"264","author":"N Suzuki","year":"1994","journal-title":"Science"},{"issue":"9","key":"pbio.3001694.ref022","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/nn0901-887","article-title":"The \u2019Arctic\u2019 APP mutation (E693G) causes Alzheimer\u2019s disease by enhanced Abeta protofibril formation.","volume":"4","author":"C Nilsberth","year":"2001","journal-title":"Nat Neurosci"},{"issue":"6","key":"pbio.3001694.ref023","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/0092-8674(93)90635-4","article-title":"Seeding \"one-dimensional crystallization\" of amyloid: a pathogenic mechanism in Alzheimer\u2019s disease and scrapie?","volume":"73","author":"JT Jarrett","year":"1993","journal-title":"Cell"},{"issue":"1","key":"pbio.3001694.ref024","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nm0197-67","article-title":"Mutant presenilins of Alzheimer\u2019s disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice","volume":"3","author":"M Citron","year":"1997","journal-title":"Nat Med"},{"issue":"8","key":"pbio.3001694.ref025","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/nm0896-864","article-title":"Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer\u2019s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer\u2019s disease.","volume":"2","author":"D Scheuner","year":"1996","journal-title":"Nat Med"},{"issue":"6727","key":"pbio.3001694.ref026","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/19077","article-title":"Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity","volume":"398","author":"MS Wolfe","year":"1999","journal-title":"Nature"},{"issue":"6665","key":"pbio.3001694.ref027","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/34910","article-title":"Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein","volume":"391","author":"B De Strooper","year":"1998","journal-title":"Nature"},{"issue":"8","key":"pbio.3001694.ref028","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1016\/j.cell.2021.03.058","article-title":"Alzheimer\u2019s-causing mutations shift Abeta length by destabilizing gamma-secretase-Abetan interactions","volume":"184","author":"M Szaruga","year":"2021","journal-title":"Cell"},{"key":"pbio.3001694.ref029","article-title":"Association of CSF Abeta38 Levels With Risk of Alzheimer Disease-Related Decline","author":"N Cullen","year":"2021","journal-title":"Neurology"},{"issue":"7409","key":"pbio.3001694.ref030","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nature11283","article-title":"A mutation in APP protects against Alzheimer\u2019s disease and age-related cognitive decline","volume":"488","author":"T Jonsson","year":"2012","journal-title":"Nature"},{"issue":"5","key":"pbio.3001694.ref031","doi-asserted-by":"crossref","first-page":"1518 e1","DOI":"10.1016\/j.neurobiolaging.2012.09.017","article-title":"Amyloid precursor protein (APP) A673T mutation in the elderly Finnish population.","volume":"34","author":"M Kero","year":"2013","journal-title":"Neurobiol Aging"},{"key":"pbio.3001694.ref032","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.nbd.2015.05.020","article-title":"Systematic analysis of time-dependent neural effects of soluble amyloid beta oligomers in culture and in vivo: Prevention by scyllo-inositol","volume":"82","author":"M Jin","year":"2015","journal-title":"Neurobiol Dis"},{"issue":"35","key":"pbio.3001694.ref033","doi-asserted-by":"crossref","first-page":"9041","DOI":"10.1523\/JNEUROSCI.1023-16.2016","article-title":"Environmental Enrichment Potently Prevents Microglia-Mediated Neuroinflammation by Human Amyloid beta-Protein Oligomers","volume":"36","author":"H Xu","year":"2016","journal-title":"J Neurosci"},{"issue":"14","key":"pbio.3001694.ref034","doi-asserted-by":"crossref","first-page":"5819","DOI":"10.1073\/pnas.1017033108","article-title":"Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration","volume":"108","author":"M Jin","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"pbio.3001694.ref035","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1038\/s41467-018-05068-w","article-title":"An in vitro paradigm to assess potential anti-Abeta antibodies for Alzheimer\u2019s disease.","volume":"9","author":"M Jin","year":"2018","journal-title":"Nat Commun"},{"issue":"5","key":"pbio.3001694.ref036","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/nn.3697","article-title":"Single App knock-in mouse models of Alzheimer\u2019s disease","volume":"17","author":"T Saito","year":"2014","journal-title":"Nat Neurosci"},{"issue":"6577","key":"pbio.3001694.ref037","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1126\/science.abm7285","article-title":"Cryo-EM structures of amyloid-beta 42 filaments from human brains","volume":"375","author":"Y Yang","year":"2022","journal-title":"Science"},{"issue":"2","key":"pbio.3001694.ref038","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.neuron.2016.07.007","article-title":"Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative Diseases","volume":"91","author":"M Bacioglu","year":"2016","journal-title":"Neuron"},{"issue":"2","key":"pbio.3001694.ref039","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00401-021-02400-5","article-title":"CSF p-tau increase in response to Abeta-type and Danish-type cerebral amyloidosis and in the absence of neurofibrillary tangles","volume":"143","author":"SA Kaeser","year":"2022","journal-title":"Acta Neuropathol"},{"issue":"6740","key":"pbio.3001694.ref040","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/22124","article-title":"Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse","volume":"400","author":"D Schenk","year":"1999","journal-title":"Nature"},{"issue":"8","key":"pbio.3001694.ref041","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1038\/78682","article-title":"Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease","volume":"6","author":"F Bard","year":"2000","journal-title":"Nat Med"},{"issue":"5","key":"pbio.3001694.ref042","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.neuron.2020.09.029","article-title":"Emerging Microglia Biology Defines Novel Therapeutic Approaches for Alzheimer\u2019s Disease","volume":"108","author":"JW Lewcock","year":"2020","journal-title":"Neuron"},{"issue":"3","key":"pbio.3001694.ref043","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/0165-5728(89)90115-X","article-title":"Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease","volume":"24","author":"S Itagaki","year":"1989","journal-title":"J Neuroimmunol"},{"issue":"2","key":"pbio.3001694.ref044","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa1211851","article-title":"TREM2 variants in Alzheimer\u2019s disease","volume":"368","author":"R Guerreiro","year":"2013","journal-title":"N Engl J Med"},{"issue":"2","key":"pbio.3001694.ref045","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1211103","article-title":"Variant of TREM2 associated with the risk of Alzheimer\u2019s disease","volume":"368","author":"T Jonsson","year":"2013","journal-title":"N Engl J Med"},{"issue":"7","key":"pbio.3001694.ref046","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.cell.2017.05.018","article-title":"A Unique Microglia Type Associated with Restricting Development of Alzheimer\u2019s Disease","volume":"169","author":"H Keren-Shaul","year":"2017","journal-title":"Cell"},{"issue":"7","key":"pbio.3001694.ref047","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.15252\/embr.201743922","article-title":"TREM2 deficiency impairs chemotaxis and microglial responses to neuronal injury","volume":"18","author":"F Mazaheri","year":"2017","journal-title":"EMBO Rep"},{"issue":"32","key":"pbio.3001694.ref048","doi-asserted-by":"crossref","first-page":"12634","DOI":"10.1074\/jbc.RA118.002352","article-title":"Molecular basis for the loss-of-function effects of the Alzheimer\u2019s disease-associated R47H variant of the immune receptor TREM2","volume":"293","author":"A Sudom","year":"2018","journal-title":"J Biol Chem"},{"issue":"1","key":"pbio.3001694.ref049","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13024-018-0262-8","article-title":"The Trem2 R47H variant confers loss-of-function-like phenotypes in Alzheimer\u2019s disease.","volume":"13","author":"PJ Cheng-Hathaway","year":"2018","journal-title":"Mol Neurodegener"},{"issue":"2","key":"pbio.3001694.ref050","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/s41593-018-0296-9","article-title":"Loss of TREM2 function increases amyloid seeding but reduces plaque-associated ApoE","volume":"22","author":"S Parhizkar","year":"2019","journal-title":"Nat Neurosci"},{"issue":"5","key":"pbio.3001694.ref051","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1084\/jem.20151948","article-title":"TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques","volume":"213","author":"Y Wang","year":"2016","journal-title":"J Exp Med"},{"issue":"4","key":"pbio.3001694.ref052","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/ana.22615","article-title":"Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders","volume":"70","author":"M Jucker","year":"2011","journal-title":"Ann Neurol"},{"issue":"12","key":"pbio.3001694.ref053","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1038\/s41593-020-00737-w","article-title":"Acute targeting of pre-amyloid seeds in transgenic mice reduces Alzheimer-like pathology later in life","volume":"23","author":"RE Uhlmann","year":"2020","journal-title":"Nat Neurosci"},{"issue":"4","key":"pbio.3001694.ref054","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S1474-4422(22)00027-8","article-title":"Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer\u2019s disease: a longitudinal observational study","volume":"21","author":"E Morenas-Rodriguez","year":"2022","journal-title":"Lancet Neurol"},{"key":"pbio.3001694.ref055","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1750-1326-9-20","article-title":"Altered microglial response to Abeta plaques in APPPS1-21 mice heterozygous for TREM2.","volume":"9","author":"JD Ulrich","year":"2014","journal-title":"Mol Neurodegener."},{"issue":"8","key":"pbio.3001694.ref056","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.neuron.2021.02.010","article-title":"Trem2 restrains the enhancement of tau accumulation and neurodegeneration by beta-amyloid pathology","volume":"109","author":"SH Lee","year":"2021","journal-title":"Neuron"},{"issue":"507","key":"pbio.3001694.ref057","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav6221","article-title":"Increased soluble TREM2 in cerebrospinal fluid is associated with reduced cognitive and clinical decline in Alzheimer\u2019s disease.","volume":"11","author":"M Ewers","year":"2019","journal-title":"Sci Transl Med"},{"issue":"5123","key":"pbio.3001694.ref058","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1126\/science.8346443","article-title":"Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer\u2019s disease in late onset families","volume":"261","author":"EH Corder","year":"1993","journal-title":"Science"},{"issue":"1","key":"pbio.3001694.ref059","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/0006-8993(91)91092-F","article-title":"Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer\u2019s disease and kuru plaque amyloid in Creutzfeldt-Jakob disease","volume":"541","author":"Y Namba","year":"1991","journal-title":"Brain Res"},{"issue":"2","key":"pbio.3001694.ref060","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nrneurol.2012.263","article-title":"Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy.","volume":"9","author":"CC Liu","year":"2013","journal-title":"Nat Rev Neurol"},{"issue":"89","key":"pbio.3001694.ref061","doi-asserted-by":"crossref","first-page":"89ra57","DOI":"10.1126\/scitranslmed.3002156","article-title":"Human apoE isoforms differentially regulate brain amyloid-beta peptide clearance","volume":"3","author":"JM Castellano","year":"2011","journal-title":"Sci Transl Med"},{"issue":"12","key":"pbio.3001694.ref062","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1084\/jem.20121274","article-title":"Anti-apoE immunotherapy inhibits amyloid accumulation in a transgenic mouse model of Abeta amyloidosis","volume":"209","author":"J Kim","year":"2012","journal-title":"J Exp Med"},{"issue":"5","key":"pbio.3001694.ref063","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/s41590-021-00913-5","article-title":"Microglia use TAM receptors to detect and engulf amyloid beta plaques","volume":"22","author":"Y Huang","year":"2021","journal-title":"Nat Immunol"},{"issue":"3","key":"pbio.3001694.ref064","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/ana.20009","article-title":"Imaging brain amyloid in Alzheimer\u2019s disease with Pittsburgh Compound-B","volume":"55","author":"WE Klunk","year":"2004","journal-title":"Ann Neurol"},{"issue":"1","key":"pbio.3001694.ref065","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","article-title":"A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer\u2019s disease with lecanemab, an anti-Abeta protofibril antibody.","volume":"13","author":"CJ Swanson","year":"2021","journal-title":"Alzheimers Res Ther"},{"key":"pbio.3001694.ref066","article-title":"Donanemab in Early Alzheimer\u2019s Disease","author":"MA Mintun","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"pbio.3001694.ref067","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s11682-018-9847-7","article-title":"PET imaging of tau protein targets: a methodology perspective","volume":"13","author":"C Lois","year":"2019","journal-title":"Brain Imaging Behav"},{"issue":"4","key":"pbio.3001694.ref068","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/ana.410380413","article-title":"Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer\u2019s disease","volume":"38","author":"R Motter","year":"1995","journal-title":"Ann Neurol"},{"issue":"9","key":"pbio.3001694.ref069","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa1202753","article-title":"Clinical and biomarker changes in dominantly inherited Alzheimer\u2019s disease","volume":"367","author":"RJ Bateman","year":"2012","journal-title":"N Engl J Med"},{"issue":"2","key":"pbio.3001694.ref070","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1474-4422(12)70291-0","article-title":"Tracking pathophysiological processes in Alzheimer\u2019s disease: an updated hypothetical model of dynamic biomarkers","volume":"12","author":"CR Jack","year":"2013","journal-title":"Lancet Neurol"},{"key":"pbio.3001694.ref071","article-title":"Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer\u2019s Disease.","author":"S Budd Haberlein","year":"2022","journal-title":"J Prev Alz"},{"issue":"7618","key":"pbio.3001694.ref072","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces Abeta plaques in Alzheimer\u2019s disease","volume":"537","author":"J Sevigny","year":"2016","journal-title":"Nature"},{"issue":"7","key":"pbio.3001694.ref073","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/s41591-021-01369-8","article-title":"A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer\u2019s disease","volume":"27","author":"S Salloway","year":"2021","journal-title":"Nat Med"},{"key":"pbio.3001694.ref074","unstructured":"FDA. Clinical Pharmacology Review 2020 [p. 25\u201331]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2021\/761178Orig1s000ClinPharm_Redacted.pdf."},{"key":"pbio.3001694.ref075","unstructured":"FDA. Office of Neurology\u2019s Summary Review Memorandum 2020 [p. 3]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2021\/Aducanumab_BLA761178_Dunn_2021_06_07.pdf."},{"key":"pbio.3001694.ref076","unstructured":"FDA. Office of Neurology\u2019s Summary Review Memorandum 2020 [p. 5]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2021\/Aducanumab_BLA761178_Dunn_2021_06_07.pdf."},{"key":"pbio.3001694.ref077","unstructured":"Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer\u2019s Disease (AD). https:\/\/clinicaltrialsgov\/ct2\/show\/NCT03443973?term=gantenerumab&cond=Alzheimer+Disease&draw=2&rank=1. 2022."},{"issue":"1","key":"pbio.3001694.ref078","doi-asserted-by":"crossref","first-page":"6024","DOI":"10.1038\/s41467-020-19543-w","article-title":"Plasma N-terminal tau fragment levels predict future cognitive decline and neurodegeneration in healthy elderly individuals.","volume":"11","author":"JP Chhatwal","year":"2020","journal-title":"Nat Commun"},{"issue":"3","key":"pbio.3001694.ref079","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41591-020-0755-1","article-title":"Plasma P-tau181 in Alzheimer\u2019s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer\u2019s dementia.","volume":"26","author":"S Janelidze","year":"2020","journal-title":"Nat Med"},{"issue":"3","key":"pbio.3001694.ref080","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41591-020-0762-2","article-title":"Diagnostic value of plasma phosphorylated tau181 in Alzheimer\u2019s disease and frontotemporal lobar degeneration","volume":"26","author":"EH Thijssen","year":"2020","journal-title":"Nat Med"},{"key":"pbio.3001694.ref081","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.cca.2021.05.011","article-title":"The PrecivityAD test: Accurate and reliable LC-MS\/MS assays for quantifying plasma amyloid beta 40 and 42 and apolipoprotein E proteotype for the assessment of brain amyloidosis","volume":"519","author":"KM Kirmess","year":"2021","journal-title":"Clin Chim Acta"},{"issue":"369","key":"pbio.3001694.ref082","doi-asserted-by":"crossref","first-page":"369ra178","DOI":"10.1126\/scitranslmed.aag1767","article-title":"Early changes in CSF sTREM2 in dominantly inherited Alzheimer\u2019s disease occur after amyloid deposition and neuronal injury","volume":"8","author":"M Suarez-Calvet","year":"2016","journal-title":"Sci Transl Med"}],"container-title":["PLOS Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pbio.3001694","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T17:24:51Z","timestamp":1658424291000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pbio.3001694"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,21]]},"references-count":82,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,7,21]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pbio.3001694","relation":{},"ISSN":["1545-7885"],"issn-type":[{"value":"1545-7885","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,21]]}}}